GLP-1 and Cardiovascular Health — What the Research Shows

For most of medical history, weight-loss medications were viewed with deep skepticism by cardiologists. The fen-phen disaster of the 1990s, along with subsequent concerns about stimulant-based appetite suppressants, had made heart doctors wary of any drug that touched the metabolic axis. GLP-1 receptor agonists have fundamentally changed that calculus.

Over the past decade, a series of large, rigorous cardiovascular outcome trials (CVOTs) have demonstrated not merely that GLP-1 drugs do not harm the heart — but that they actively protect it. The cardiovascular data for semaglutide is now among the most compelling in all of preventive cardiology. Understanding what this research shows, and what it means for patients, is essential context for anyone considering GLP-1 therapy.

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic the effects of the GLP-1 hormone, which is naturally released from the gut after eating. They were originally developed for type 2 diabetes because of their ability to lower blood sugar without causing dangerous hypoglycemia. In clinical trials, researchers noticed something unexpected: patients were also losing significant weight. Further investigation revealed a cascade of cardiometabolic benefits beyond glycemic control — many of which appear to be at least partially independent of weight loss itself.

Approved GLP-1 medications include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound), which also activates the GIP receptor. This article focuses primarily on semaglutide, which has the most robust cardiovascular outcome data.

The SELECT Trial: A Landmark in Cardiovascular Medicine

Study Design

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) was published in the New England Journal of Medicine in November 2023 and stands as the most important cardiovascular trial in the GLP-1 class to date. Crucially, it studied cardiovascular outcomes in people without type 2 diabetes — a first for this drug class.

SELECT enrolled 17,604 adults aged 45 and older with pre-existing cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease), a BMI of ≥27, and no history of diabetes. Participants were randomized to weekly semaglutide 2.4 mg or placebo and followed for a median of approximately 40 months (just over 3 years).

Key Findings

• 20% relative risk reduction in major adverse cardiovascular events (MACE) — defined as cardiovascular death, nonfatal heart attack, or nonfatal stroke — in the semaglutide group compared to placebo (6.5% vs. 8.0%; HR 0.80, 95% CI 0.72–0.90; p<0.001)
• The benefit was consistent across all pre-specified subgroups, regardless of BMI, age, sex, or geography
• Cardiovascular death was reduced by 15% (HR 0.85, though this did not reach statistical significance as a standalone endpoint)
• The reduction in MACE events appeared to begin within the first few months of treatment and continued to accumulate over the follow-up period
• Benefits occurred alongside meaningful weight loss (average 9.4% vs. 0.9% in placebo), but the magnitude of cardiovascular protection could not be fully explained by weight loss alone — suggesting direct cardioprotective mechanisms

SELECT established, for the first time, that a weight-loss medication can reduce the risk of major cardiac events in people with cardiovascular disease who do not have diabetes. This is a paradigm-shifting result that has prompted major cardiology societies to update their guidance on GLP-1 therapy.

The LEADER Trial: Liraglutide in Type 2 Diabetes

Published in 2016, the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was one of the earliest large CVOTs to demonstrate cardiovascular benefit for a GLP-1 drug. In 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide 1.8 mg vs. placebo over 3.8 years resulted in:

• 13% relative risk reduction in the 3-point MACE endpoint (13.0% vs. 14.9%; HR 0.87, 95% CI 0.78–0.97; p=0.01)
• Significant reductions in cardiovascular death (22% relative reduction)
• Reductions in microvascular outcomes including kidney disease progression

LEADER helped establish that GLP-1 cardiovascular benefits were not unique to semaglutide and laid the groundwork for subsequent, larger trials.

The SUSTAIN-6 Trial: Early Evidence for Semaglutide

The SUSTAIN-6 trial, published in 2016, was a cardiovascular safety trial for semaglutide in type 2 diabetes that unexpectedly demonstrated a significant reduction in MACE (26% relative reduction vs. placebo; HR 0.74, 95% CI 0.58–0.95). While the trial was not powered to demonstrate superiority — and the result was in some ways a surprise — it provided the first signal that semaglutide's cardiovascular effects were substantial and prompted the much larger SELECT trial.

Mechanisms: How GLP-1 Drugs Protect the Heart

Researchers have identified multiple mechanisms through which GLP-1 agonists may reduce cardiovascular risk, some weight-dependent and some apparently independent of weight loss:

1. Weight Loss and Fat Reduction

Obesity is one of the strongest independent risk factors for cardiovascular disease. Excess adipose tissue — particularly visceral fat surrounding the abdominal organs — promotes chronic inflammation, insulin resistance, dyslipidemia, and hypertension. GLP-1-driven weight loss directly reduces these risk factors. Even a 5–10% reduction in body weight is associated with measurable improvements in blood pressure, triglycerides, HDL cholesterol, and inflammatory markers.

2. Blood Pressure Reduction

Multiple trials have documented consistent, modest reductions in systolic blood pressure with GLP-1 therapy — typically 3–5 mmHg. This may seem small, but at the population level, a 3 mmHg reduction in systolic blood pressure is estimated to reduce stroke risk by approximately 8% and coronary heart disease risk by approximately 5%. The mechanism appears to involve direct vasodilatory effects via GLP-1 receptors present in blood vessel walls, as well as natriuretic (sodium-excreting) effects in the kidney.

3. Reduction in Systemic Inflammation

Chronic low-grade inflammation is a central driver of atherosclerosis — the buildup of plaque in artery walls that leads to heart attacks and strokes. GLP-1 receptors are expressed on immune cells including macrophages, and GLP-1 agonism has been shown to reduce pro-inflammatory cytokines such as IL-6, TNF-alpha, and CRP. In SELECT, participants on semaglutide showed significant reductions in high-sensitivity CRP (hsCRP), a key biomarker of vascular inflammation, independent of weight loss.

4. Improvement in Lipid Profile

GLP-1 therapy is associated with modest but consistent improvements in lipid parameters, including reductions in triglycerides and LDL cholesterol and increases in HDL cholesterol. These effects are partly mediated by weight loss but may also reflect direct effects on hepatic lipid metabolism.

5. Endothelial Function

The endothelium — the inner lining of blood vessels — plays a crucial role in regulating vascular tone and preventing clot formation. Obesity and diabetes impair endothelial function significantly. GLP-1 agonists have been shown in mechanistic studies to improve endothelial function, reduce oxidative stress in vessel walls, and decrease the expression of adhesion molecules that facilitate plaque formation.

6. Direct Cardiac Effects

GLP-1 receptors are expressed in cardiac tissue. Animal and human studies have suggested that GLP-1 agonism may have direct cardioprotective effects including improved cardiac contractility, reduced ischemia/reperfusion injury, and favorable effects on cardiac remodeling after injury. The clinical significance of these direct effects in humans is still being investigated.

Cardiovascular Outcomes Summary Table

Trial	Drug	Population	MACE Reduction	Key Finding
SELECT (2023)	Semaglutide 2.4 mg	Obesity + CVD, no diabetes	20% (HR 0.80)	First CVOT in obesity without diabetes
SUSTAIN-6 (2016)	Semaglutide 1 mg	T2D + high CV risk	26% (HR 0.74)	Early semaglutide CV signal
LEADER (2016)	Liraglutide 1.8 mg	T2D + high CV risk	13% (HR 0.87)	First GLP-1 CVOT to show superiority
REWIND (2019)	Dulaglutide 1.5 mg	T2D ± prior CVD	12% (HR 0.88)	Benefit in lower-risk T2D patients

Who Benefits Most from GLP-1 Cardiovascular Protection?

The cardiovascular benefits of GLP-1 therapy appear to be most pronounced in specific populations:

• People with established atherosclerotic cardiovascular disease (prior heart attack, stroke, or PAD) — this was the SELECT trial population and the group with the clearest absolute benefit
• People with type 2 diabetes and high CV risk — the population studied in LEADER, SUSTAIN-6, and REWIND
• People with obesity and multiple cardiovascular risk factors — hypertension, dyslipidemia, prediabetes, metabolic syndrome
• People with heart failure with preserved ejection fraction (HFpEF) — an emerging indication; trials like STEP-HFpEF have shown significant improvement in heart failure symptoms and exercise capacity with semaglutide

Kidney Benefits: An Emerging Story

Cardiovascular and renal health are deeply intertwined, and GLP-1 drugs appear to offer renal protection as well. The FLOW trial (2024) demonstrated that semaglutide significantly reduced the risk of major kidney disease events — including end-stage renal disease and doubling of serum creatinine — in patients with type 2 diabetes and chronic kidney disease. This makes GLP-1 therapy relevant not just to cardiologists but to nephrologists as well.

Cardiometabolic Benefits Beyond Weight Loss

A critical insight from the SELECT trial data analysis is that approximately 40–50% of the cardiovascular benefit observed could not be explained by weight loss alone. When researchers performed statistical adjustments controlling for the degree of weight loss, a substantial residual benefit remained — suggesting direct anti-inflammatory, endothelial, and vascular mechanisms that operate independently of body weight change.

This means that even patients who are modest responders in terms of weight loss may still derive meaningful cardiovascular protection from GLP-1 therapy — an important consideration for clinical decision-making.

GLP-1 Therapy and Heart Failure

Heart failure with preserved ejection fraction (HFpEF) is one of the most common forms of heart failure and has historically been difficult to treat — few medications have demonstrated clear benefit. A 2023 trial, STEP-HFpEF, evaluated semaglutide 2.4 mg in 529 patients with HFpEF and obesity, and found significant improvements in:

• Kansas City Cardiomyopathy Questionnaire (KCCQ) score, a validated measure of heart failure symptoms and quality of life — improving by 7.8 points more than placebo
• Six-minute walk distance (an objective measure of exercise capacity) — improving by 20 meters more than placebo
• Body weight — reduced by 13.3% vs. 2.6% for placebo
• C-reactive protein (inflammatory marker) — reduced significantly

These findings have elevated GLP-1 therapy to a new level of relevance in heart failure management, and several professional cardiology societies have begun incorporating GLP-1 recommendations into their HFpEF management guidelines.

Important Caveats and Who Should Not Use GLP-1 for CV Benefit

While the cardiovascular evidence for GLP-1 therapy is compelling, it is important to acknowledge its limitations and contraindications:

• Not studied in advanced heart failure with reduced ejection fraction (HFrEF): The available data is primarily in patients with preserved ejection fraction and atherosclerotic cardiovascular disease. The benefits may not extend equally to all forms of heart disease.
• Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2: Both semaglutide and tirzepatide carry boxed warnings for this rare but serious risk.
• Pancreatitis history: GLP-1 drugs are generally avoided in patients with a personal history of pancreatitis.
• Severe GI motility disorders: Because GLP-1 drugs slow gastric emptying, they are generally not used in patients with gastroparesis.

For patients with complex cardiovascular histories, coordination between the telehealth prescribing team and the patient's cardiologist or primary care physician is best practice. Truventa's clinical team can support that communication.

Accessing GLP-1 Therapy Through Truventa Medical

For patients with cardiovascular risk factors or established heart disease, GLP-1 therapy represents one of the most evidence-based interventions available for reducing future cardiac events. Truventa Medical offers access to semaglutide-based treatment programs via telehealth, with licensed physicians available in all 50 states. Our clinical team works with you to evaluate your cardiovascular risk profile, coordinate with your existing cardiac care team where appropriate, and design a treatment program suited to your goals.

No office visit is required to get started. Results may vary based on individual health status, adherence, and lifestyle factors.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Results may vary. Consult your doctor before starting any new treatment.